BioSpace News Archive

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 1,800 shares of Astria’s common stock on February 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

IVERIC bio, Inc. reported that on February 1, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2023.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.

Johnson & Johnson will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA.

Sesen Bio, Inc. filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.

Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a price to the public of $3.98 per share and warrant.